Sensus Healthcare NASDAQ: SRTS reported lower third-quarter revenue despite shipping more superficial radiation therapy systems, as product mix and the absence of sales to its historically largest customer weighed on the top line.
Sensus Healthcare is currently navigating a challenging period of operational deleveraging, characterized by a sharp decline in top-line revenue from $12.6M in 2023Q4 to $3.4M in 2026Q1.
Price trend, volume and key moving averages
Trailing total returns as of 11/18/2026, which may include dividends or other distributions. Benchmark is S&P 500 (^GSPC).
Check whether operating performance supports the current valuation.
Recent results and news deserve attention only when they alter the forward view.
| Quarter | EPS (Act vs Est) | Revenue (Act vs Est) |
|---|---|---|
Q4 2026Latest Nov 12, 2026 | -$0.09-63.6% vs -$0.06 | $6M-9.4% vs $7M |
Q3 2026 Aug 13, 2026 | -$0.53-324.0% vs -$0.13 | $2M-50.2% vs $5M |
Q2 2026 May 7, 2026 | -$0.16-28.0% vs -$0.13 | $3M-36.2% vs $5M |
Q1 2026 Feb 12, 2026 | -$0.19-245.5% vs -$0.06 | $5M-40.8% vs $8M |
Sensus Healthcare NASDAQ: SRTS reported lower third-quarter revenue despite shipping more superficial radiation therapy systems, as product mix and the absence of sales to its historically largest customer weighed on the top line.
Sensus Healthcare, Inc. (SRTS) Q3 2026 Earnings Call Transcript
BOCA RATON, Fla.--(BUSINESS WIRE)--Sensus Healthcare, Inc. (Nasdaq: SRTS), a medical device company committed to providing highly effective, non-invasive treatments for oncological and non-oncological skin conditions, today announced financial results and business highlights for the three months ended September 30, 2026. Highlights included: Revenues of $6.0 million compared with $6.9 million in the third quarter of 2025, reflecting a product mix of lower-priced SRT-100 systems and the absence.
BOCA RATON, Fla.--(BUSINESS WIRE)--Sensus Healthcare, Inc. (Nasdaq: SRTS), a medical device company committed to providing highly effective, non-invasive treatments for oncological and non-oncological skin conditions, today announced the sale of its 1,000th superficial radiotherapy (SRT) system, representing an important achievement in the Company's commercial development. This sale underscores Sensus' continued efforts to expand access to SRT as a non-invasive treatment option for non-melanoma.
Benchmark SRTS against direct peers instead of judging its metrics in isolation.
Key metrics vs top competitors for Sensus Healthcare, Inc. (SRTS)
| Company | Price | Market Cap | P/E Ratio | Rev Growth (1Y) | Net Margin | ROE | Div Yield |
|---|---|---|---|---|---|---|---|
| $2.26 | $37.2M | -2.32 | -34.26% | -96.49% | -38.65% | — | |
| $1.62 | $712.96K | -0.10 | -100% | — | — | — | |
| $0.88 | $86.39M | -4.05 | 20.28% | -70.86% | -108.55% | — | |
| $2.44 | $7.32M | -0.49 | -12.34% | -4.41% | -36.6% | — | |
| $430.53 | $152.1B | 51.19 | 20.51% | 25.54% | 16.91% | — | |
| $243.25 | $14.35B | -87.67 | 32.33% | -24.6% | -24.91% | — |
Sensus Healthcare, Inc. (SRTS) vs competitors — business, growth, and fundamentals comparison against the closest industry rivals.
Verify the primary filings, follow material updates, and answer the remaining questions.
Sensus Healthcare, Inc. (SRTS) SEC filings — annual & quarterly reports (10-K, 10-Q)
Nov 12, 2026·SEC
Aug 13, 2026·SEC
Jun 5, 2026·SEC
Get notified when SRTS posts new earnings or crosses analyst targets
Free. No account needed. Unsubscribe any time.
Sensus Healthcare, Inc. (SRTS) stock FAQ — growth, dividends, profitability & financials explained
Sensus Healthcare, Inc. (SRTS) reported $16.6M in revenue over the trailing twelve months. Revenue was $27.5M in fiscal year 2025. That is 373% more than the $5.8M of fiscal year 2014.
Sensus Healthcare, Inc. (SRTS) revenue fell by 53.3% over the trailing twelve months, compared with the twelve months before.
No. Sensus Healthcare, Inc. (SRTS) reported a net loss of $16.0M over the trailing twelve months.
Sensus Healthcare, Inc. (SRTS) had a return on equity (ROE) of -38.7% over the trailing twelve months. A negative ROE means the company lost money over the period.
Sensus Healthcare, Inc. (SRTS) had negative free cash flow of $11.5M over the trailing twelve months.